Fourth Friday at Four: Zomedica Clinical Studies Deep Dive - ZOMEDICA CORP

Based on the provided transcript, here are the extracted and summarized forward-looking statements from Zomedica's Fourth Friday at Four Investor Webinar:

• Explicit Guidance:

  • Cash Flow Positive: Management expects to achieve cash flow positivity in the fourth quarter of 2026 (referred to as "this year" relative to the Oct 23, 2026 transcript date), driven by a record Q4 top-line revenue.
  • Profitability (Adjusted EBITDA): The company targets being Adjusted EBITDA positive (GAAP excluding depreciation and amortization) in 2027.
  • R&D Expense Outlook: R&D expenses for 2027 are expected to be lower than 2026 levels, as several key product projects are nearing market completion, contributing to the path to profitability.
  • Q4 2026 Revenue: Management expresses confidence in achieving increased top-line revenue in Q4 2026, citing historical seasonal performance.

• Business-Segment Outlook:

  • Truforma Platform (Equine): Significant growth in the equine segment is anticipated over the next year following the launch of new assays; this segment is described as the "fastest growing" with high penetration relative to the smaller addressable market (approx. 2,400 equine-only accounts in the US).
  • Truforma Platform (New Assays): Three new equine assays are scheduled for launch at the upcoming AAEP meeting in early December 2026, with one potentially not available for shipment until January 2027. A new variation of a small animal assay is also planned for this year.
  • Feline Pharma Partnerships: The company is in the "early evaluation phase" with potential feline pharma partners for new assays; no timeline is provided, and management cautions against treating this as a confirmed milestone.
  • Consumables Revenue: Consumables are projected to represent approximately 70% of total company revenue, with Truforma revenue being 100% consumable-based. Cartridge orders per analyzer are expected to increase as placement growth accelerates.
  • PulseVet & PIMS: The full-scale launch of the PIMS (Practice Information Management System) integration for existing and new products is targeted for December 2026 (specifically around the AAEP conference), ahead of the previous January target.
  • Loop Products (Retail): Continued growth is expected in the retail market for Assisi Loop devices sold directly to pet parents.
  • AC/CG/VetaGel: Steady demand for hemorrhage control products (AC) and VetaGel is anticipated, with continued uptake in hospice and clinical settings.

• Market and Competitive Outlook:

  • Capital Structure/Listing: Zomedica has an active plan to uplist from the OTC to the NYSE, but requires an increase in share price (currently below the $1 billion market cap threshold given share count) to meet requirements. Management states they will either address the capital structure or "grow like heck" to achieve the price point.
  • Large Group Partnerships: Accelerated growth is expected in 2027 by signing nationwide agreements with major veterinary hospital chains (e.g., VMG, NVA, VetCorps) via a dedicated corporate accounts team. Critical mass for these negotiations is expected by early 2027.
  • Commercialization Strategy: Future product launches in late 2026 and 2027 are expected to drive revenue growth sufficient to reach EBITDA positivity.
  • Human Health: Management declined to discuss potential human health FDA clearances (e.g., diabetic foot ulcers) or sports medicine applications, citing that the current focus remains strictly on the veterinary market due to regulatory costs and strategic alignment.

• Macro / Industry Outlook:

  • Regulatory Strategy: The company intends to maintain rigorous adherence to fair disclosure regulations; no material M&A or product details will be disclosed prior to public announcements to avoid giving competitors a strategic advantage.
  • Market Dynamics: Management notes that while institutional investors are attractive for capital support, the current market structure (lack of large institutional buying) has suppressed share price despite strong fundamentals.

• Strategic Initiatives:

  • Operational Restructuring: Cost reductions from 2026 restructuring efforts (eliminated positions) are expected to provide full-year benefits in 2027, reducing the operating expense base while maintaining revenue growth.
  • Capital Allocation: The company will retain capital for growth and balance sheet strength until cash flow positivity is achieved; stock buybacks are conditional upon reaching cash flow positive status and will be executed gradually.
  • Product Development: A focus on "evidence-based" commercialization, where clinical studies precede or accompany product launches to drive adoption (Land, Deepen, Expand framework).
  • International Expansion: Continued growth in non-US markets (including Canada and other countries) for Truforma is anticipated.

• Risks and Headwinds to Outlook:

  • Share Price Threshold: The primary hurdle to NYSE uplisting is the current share price; failure to grow the share price or restructure capital could delay or prevent the uplisting.
  • Assay Development Timelines: Specific assay launches (e.g., the fourth equine assay) face potential delays due to material constraints; no guarantees are given on specific launch dates for new platforms.
  • Human Health Expansion: The transcript highlights that pursuing FDA clearance for human indications (e.g., sports medicine, diabetic care) is not currently planned due to the significant cost and strategic focus on the animal market.
  • Revenue Dependency: Profitability targets (EBITDA positive in 2027) are contingent on a combination of expense discipline and continued revenue growth; reducing expenses alone is insufficient.

• Management Tone on the Future:

  • Confidence: Management expressed high confidence in hitting cash flow positivity in Q4 2026 and EBITDA positivity in 2027.
  • Operational Discipline: The tone reflects a shift from "investment mode" to "efficiency mode," emphasizing that R&D spending will decrease as projects mature while operational expenses are being optimized.
  • Transparency: Management emphasized a commitment to evidence-based storytelling and direct shareholder communication, noting that the company avoids pre-announcing non-material details to protect competitive advantage.
  • Future Outlook: The outlook is characterized by a belief in "inevitable growth" for consumable revenue (specifically Truforma) and a strategic pivot toward large-scale enterprise partnerships in 2027.

• Miscellaneous:

  • Next Webinar: The next "Fourth Friday at Four" session is scheduled for November 20, 2026 (moved to the third Friday of November to accommodate Thanksgiving), focusing on Human Resources.
  • December Session: There will be no Fourth Friday webinar in December 2026.
  • Share Buyback Timing: No immediate buybacks are planned; consideration will resume only after cash flow positivity is established.